BHPG

British Hepatology Pharmacy Group. Affiliate group of BASL for pharmacists and pharmacy technicians aiming to develop knowledge/understanding of liver disorders

[BHPG @heppharm]

What a great educational day we had and to see all the representation we have across the UK on #hepatology #pharmacy!

We will have many more events in the future, join us if you haven’t. It’s only £20!

https://t.co/LE86O8cSzy

[Elliot Tapper @ebtapper]

Naltrexone should be first line for AUD in people with cirrhosis
It is increasingly uncomfortable to see baclofen mentioned alongside it, or even acamprosate

[BHPG @heppharm]

Only 2 weeks left to our annual educational event in London! Have a look and sign up now to not miss your chance!

Register here: https://t.co/fVJXr2RNIs

[BASL education feed @BASLedu]

Further information on the BASL website https://t.co/V085n2Vx8z
or register via this link https://t.co/idPImfL14F

[BHPG @heppharm]

Another successful year at #BASL2025! Great to see all the inspiring 💫 work from #pharmacy.

See you all at the next BHPG meeting on 25 Nov! It’s 🆓 for BASL members!

See details 👇
📍44 Hallam Street, London
🔗 https://t.co/Cj2ZKN2ldc…
ℹ️ https://t.co/ty34N9xLae…

[NEJM @NEJM]

The prognosis of liver disease depends on the extent of fibrosis, which is usually staged with the use of liver biopsy. The limitations of biopsy have led to the development of noninvasive tests, which Drs. Laurent Castera, Mary E. Rinella, and Emmanuel A. Tsochatzis review. Learn more: https://t.co/oZ93UDdEiA

[BASL education feed @BASLedu]

Further information on the BASL website https://t.co/V085n2Vx8z
or register via this link https://t.co/idPImfL14F

[Debbie Shawcross @DebbieShawcros1]

Complications of Proton Pump Therapy 💊

One of the best figures I’ve seen in a long time.

On your next ward round or in the clinic think about whether your patient really needs to be on a PPI. #GITwitter #livertwitter #gutmicrobiome
#AMR

https://t.co/NwOXRpSPhg

[Frontline Gastro @FrontGastro_BMJ]

🟢 10/14 | BASL × FG Special Issue

“Personalised treatment is reshaping how we manage difficult autoimmune hepatitis.”

🧬 Optimised thiopurine therapy + metabolite monitoring now standard of care
💊 MMF established as leading 2nd-line — and viable 1st-line in select cases
🧪 Tacrolimus, infliximab & rituximab emerging for refractory disease

📰 Read the full review ➡️ https://t.co/BIma7pTpd2

#AutoimmuneHepatitis #Hepatology #FGBASLSpecialIssue

@basl_events @heppharm @livernursing @LiverAHPs @Liver4Lifeuk @f4liverresearch @IQILS_Liver @LiverTrust @EASLedu @EASLnews @BritSocGastro @BavenoCoop @BCLC_group @ILCAnews @APASLnews @liverfellow @my_ueg @UKCPAGastro
@PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BSGtrainees @drkeithsiau @ebtapper @DrLChina @acv69cardenas @GeriKeane @jamesbmaurice @ClinicLiver

[BHPG @heppharm]

🔔 Useful tools and information for all pharmacists helping to write and implement clinical guidelines for #hepatology in 🇬🇧

[EASLnews @EASLnews]

📢 NEW! EASL’s new Guidelines Dissemination Programme advances liver care by promoting awareness and uptake of Clinical Practice Guidelines. Its key initiative, the EASL Guidelines Implementation Programme, turns recommendations into practical tools for everyday use.

Discover the first edition focused on the EASL–EASD–EASO CPGs for #MASLD: EASL MASLD Guidelines Implementation Programme: https://t.co/rsRsl8XfE9

#LiverTwitter #LiverX @DebbieShawcros1 @analleo @FrancqueSven @MajaThiele

[BHPG @heppharm]

Another successful year at #BASL2025! Great to see all the inspiring 💫 work from #pharmacy.

See you all at the next BHPG meeting on 25 Nov! It’s 🆓 for BASL members!

See details 👇
📍44 Hallam Street, London
🔗 https://t.co/Cj2ZKN2ldc…
ℹ️ https://t.co/ty34N9xLae…

[BHPG @heppharm]

Always lovely to hear great engagement and response from our efforts! ✨

@Yun_Pharmacist definitely outdid herself on summarising the use of GLP1RA and the future of MASLD therapy for all of us.

[Gemma Botterill @botterill_gemma]

GLP-1 agonists: Benefits and challenges. One of the hottest topics at the moment in light of MASLD/MASH (shown by the amount of ppl who left after the talk to go back to the medics meeting!!). Thank you @Yun_Pharmacist for a great informative talk @heppharm @livernursing @BASLedu

[BHPG @heppharm]

Posters @ #BASL2025: @ClaireBullen13 presents data on repatriating immunosuppression prescribing to referral hospitals, enabling transplant recipients access care closer to home and align with the #NHS 10 year plan ambitions.

@CUH_CambsLiver @CUH_NHS

[BHPG @heppharm]

Posters @ #BASL2025: Hannah Hesketh presents data on terlipressin use in HRS-1 post MHRA alert.

We are currently collecting more 🇬🇧 data on this topic, please contact [email protected] for more information.

@geshNHS #research

[BHPG @heppharm]

Arron Jones presenting on current and emerging treatment options for #PBC, highlighting data collected from our group on elafibranor.

#BASL2025 @NHSBartsHealth @PBCFoundation @BASLedu @LiverAHPs

[BHPG @heppharm]

Posters @#basl2025: Sinead Peare presents her data on @GSTTnhs #pharmacist led #HBV clinic, a valuable resource to the service in treating a vastly increasing patient cohort

[BHPG @heppharm]

Our vice chair Yun Jung Kim giving an excellent in depth talk on the current situation of GLP1RAs in #MASLD and how patients can access treatment.

@BASLedu @LiverAHPs #BASL2025

[BASL education feed @BASLedu]

Great to see so many delegates at #BASL2025!

Perfect time to highlight our next event!

Intro to hep day in London - 7th Nov 25 in London

Link to registration: https://t.co/VvUkFgeFrF

[BHPG @heppharm]

Posters @ #BASL2025: @fatemajessa presents her work on a digital referral to drive efficiency in referring rifaximin patients to primary care, improving patient access in treating hepatic encephalopathy.

@RoyalFreeNHS

[BHPG @heppharm]

Congrats to our research pharmacist Aaron Jones from Bart’s 🥇 on an excellent abstract and presentation on fracture risk in decomp cirrhosis @ #BASL2025.

[Gemma Botterill @botterill_gemma]

BLNA 2025 D2 PM kicked off with the oral presentations! Home-based virtual prehabilitation @katiesramos, Fracture risk in decomp cirrhosis (Arron Jones) @heppharm, Enhancing HCC care & The impact of a CNS led holistic needs Ax on a patients HCC journey @BASLedu @livernursing

[BHPG @heppharm]

@robelliotcooke representing #pharmacy on discussing challenges in treating #MASLD and promoting our future role in improving outcomes, such as initiating and titrating anti-diabetic/ 🫀medications and choosing appropriate antidepressants.

#basl2025 @BASLedu @LiverAHPs